Skip to content

Clinical trials

Stomach Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Stomach Neoplasms Country / region: China Clear all

1,060 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20045
20052
20064
20078
20088
20098
201010
201117
201230
201332
201427
201545
201646
201758
201853
201955
202064
202191
202289
202399
2024125
2025102
202678

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status404
Recruiting259
Completed229
Not yet recruiting67
Active, not recruiting54
Terminated24
Enrolling by invitation14
Withdrawn7
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University45
Fujian Medical University38
Peking University32
Tianjin Medical University Cancer Institute and Hospital29
Sun Yat-sen University27
Nanfang Hospital, Southern Medical University24
RenJi Hospital21
The First Affiliated Hospital with Nanjing Medical University20
Zhejiang Cancer Hospital20
Ruijin Hospital19

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Stomach Neoplasms1,060
Esophageal Neoplasms70
Colorectal Neoplasms67
Pancreatic Neoplasms57
Breast Neoplasms47
Lung Neoplasms35
Colonic Neoplasms29
Neoplasms26
Liver Neoplasms25
Ovarian Neoplasms25

Trials

Showing 26 to 50 of 1,060. Each trial links to its page on Pharma Observatory.

960 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.